Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Fetal Neonatal Med. 2005 Apr;10(2):115-22. Epub 2005 Jan 25.

The use of unlicensed and off-label medicines in the neonate.

Author information

  • 1Academic Division of Child Health (University of Nottingham), The Medical School, Derbyshire Children's Hospital, Uttoxeter Road, Derby DE22 3DT, UK. sharon.conroy@nottingham.ac.uk

Abstract

The use of unlicensed and off-label medicines in neonates in intensive care is common and widespread. Up to 93% of babies receive at least one unlicensed or off-label medicine during their stay in intensive care. Such practice is an essential part of their care and should be done based on the best evidence available. However, problems arise - on an every-day basis - because of the lack of appropriate information and licensed medicine formulations for neonates. These problems include the selection of appropriate medicine and dose, administration and the increased risk of medication errors. Initiatives to improve the situation are underway in the US and are proposed in Europe. However, more urgent action is required to stop these babies continuing to be deprived of their basic human rights to safe, effective and high-quality therapy.

PMID:
15701577
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk